Adult Dosing
Pediatric Dosing
Immunization (6 wks-6 yrs)
- Vaccination series consists of 5 doses administered as follows
- 0.5 mL IM x 3 at 2, 4, and 6 months of age at intervals of 4-8 wks (primary immunization)
- 0.5 mL IM at 15-20 months of age (booster dose)
- 0.5 mL IM at 4-6 yrs of age (booster dose)
- First dose may be given as early as 6 wks. Recommended interval between 3rd and 4th dose is 6-12 months; give 5th dose before kindergarten entry. 5th dose is not needed if 4th dose was given after 4th birthday
Notes- If dose of pertussis vaccine cannot be given, DT vaccine should be given as needed to complete the series
- For IM administration only. Not for intradermal, subcutaneous, IV, or intra-arterial administration
- Use same brand of DTaP (Daptacel, Infanrix, Tripedia) vaccine for all doses in the immunization
[Outline]
- The stopper of the vial contains dry natural latex rubber and can cause allergic reactions in latex sensitive individuals
- If prior vaccine causes Guillain-Barré syndrome within 6 weeks, a decision should be made whether to give any tetanus toxoid-containing vaccine, based on careful consideration of the potential benefits and possible risks. Give other available vaccines if decision is made to withhold tetanus toxoid
- If adverse event such as temperature >40.5oC (105oF) within 48 hours not due to another identifiable cause, collapse or shock-like state within 48 hours, persistent, inconsolable crying lasting
3 hrs within 48 hours, seizures with or without fever within 3 days occurs, the decision to give any pertussis-containing vaccine should be based on careful consideration of the potential benefits and possible risks. If pertussis component is withheld, continue with DT vaccine - Tetanus, diphtheria toxoid, acellular pertussis vaccine can cause hemorrhage when given to infants or children with coagulation disorder, including thrombocytopenia, or to those on anticoagulant therapy.
- Apnea following intramuscular vaccination has been reported in some infants born prematurely, hence based on individual infant’s medical status, and the potential benefits and possible risks of vaccination, a decision should be made when to administer an intramuscular vaccine
- Patient’s immunization history should be reviewed for possible vaccine hypersensitivity prior to administering any vaccine. Epinephrine and other appropriate agents should be made available in case an anaphylactic or acute hypersensitivity reaction occurs
- Institute of Medicine has concluded that there is a causal relationship between whole-cell pertussis DTP vaccine and acute neurologic illness. The decision to administer a pertussis-containing vaccine to children with stable central nervous system disorders, should be made on individual basis with consideration of all relevant factors, and assessment of potential risks and benefits for that individual
- As per the ACIP published guideline except for reconstitution of tetanus, diphtheria toxoid, acellular pertussis vaccine with ActHIB vaccine for administration of the fourth dose to children 15-18 months of age, it should not be combined through reconstitution with any vaccine
- Take special care to ensure that the injection does not enter a blood vessel
- The expected immune response will not be obtained if vaccine is administered to immunocompromised persons, or persons receiving immunosuppressive therapy
Cautions: Use cautiously in
- Latex sensitivity
- History of reaction to pertussis vaccine
- Guillian-Barre syndrome within 6 wks of prior tetanus vaccine
- Risk factors for seizures
- Immunosuppressed patients
- Concurrent immunosuppressants
- Coagulation disorder
- Anticoagulant use
Pregnancy Category:C
Breastfeeding: Not applicable
